Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1244 participants.

Also called NCT07116928

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,244 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07116928
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07116928. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-30 (anticipated); primary completion 2031-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Acronym
GLOW-CKD
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
ganagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07116928
Content hash
6846cbe440dac403dcc508c02b0653cf729ef93c90a5202d01b9437e28640c16